New NHS program to find and cure hidden hepatitis C

1 August 2022

Thousands more people in the UK will get potentially life-saving treatment for hepatitis C thanks to a new National Health Service (NHS) screening pilot – driving forward the NHS ambition to eliminate the virus by 2030.

NHS England today announced that the new scheme, which will begin next month, could help up to 80,000 people unknowingly living with hepatitis C to get a life-saving diagnosis and treatment sooner.

The NHS will identify people who might have the virus by searching health records for a number of key hepatitis C risk factors, such as historic blood transfusions or those with HIV.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK